**Pfizer Limited**
The Capital, 1802 / 1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

March 24, 2017

The Department of Surveillance
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

***Kind Attention: Mr. Avishkar Naik, Chief Manager***

Dear Sir,

**Re: Clarification on published news**

This refers to your letter No. NSE/CM/Surveillance/6700 dated March 24, 2017 received by email today at 3.04 pm seeking clarification on the news item captioned "Pfizer's Hospira Vizag Unit Receives 11 observations from US FDA" which appeared on CNBC TV18 on March 24, 2017.

We wish to inform you that the above news item does not relate to Pfizer Limited, India and Pfizer Limited, India has no information/knowledge in respect of the same. The said news item appears to be related to the export oriented manufacturing facility of Hospira Healthcare India Pvt. Ltd., an unlisted Indian subsidiary of Pfizer Inc. USA. Hence, Pfizer Limited, India will not be able to comment on the said news item.

Rest assured, if and when Pfizer Limited makes any announcement regarding any material development in respect of our business, we will ensure that we continue to follow the mandated procedure of informing stock exchanges in a timely manner, so as to ensure uniform and simultaneous disclosure to all the investors.

Thanking you,

Yours truly,
**For Pfizer Limited**

**Prajeet Nair**
**Company Secretary**

CIN: L24231MH1950PLC008311
contactus.india@pfizer.com
www.pfizerindia.com